MicroRNAs (miRNAs) pleiotropically modulate gene expression in all cell types. Many miRNAs are overexpressed in tumors, and recent findings suggest that tumors can be 'addicted' to miRNA overexpression, yielding a possible therapeutic opportunity.
MicroRNAs (miRNAs) are small noncoding RNAs that function primarily to negatively regulate mRNA stability of protein-coding genes [1] . This regulation is achieved by the binding of a miRNA to the 3 0 untranslated region (UTR) of a protein-coding mRNA that harbors a 'seed' sequence, typically complementary to 2-8 nucleotides from the 5 0 end of the miRNA, and the promotion of mRNA degradation. miRNAs have been implicated in a wide range of developmental and physiological processes, and recently accumulating evidence indicates that miRNAs may play significant roles in a variety of human tumors [2] . Thus, miRNA expression profiles have been associated with particular cancer types, where they may be useful as diagnostic and/or prognostic classifiers [3] , and some miRNAs have been reported to demonstrate oncogenic and tumor suppressor properties [4] . Consistent with functional roles in tumorigenesis, some miRNAs have been identified that regulate cancer-associated processes, including metastasis, invasion, and self-renewal [5, 6] .
A recent report in Nature by Medina et al. [7] described findings that highlight another aspect of miRNAs in cancer -'oncomiR addiction'. The concept of 'oncogene addiction', which refers to the acquired dependency of tumor cells on a single oncoprotein or oncogenic pathway for sustained viability or proliferative potential [8] , has gained considerable attention in recent years, due in large part to the therapeutic opportunity that this phenomenon presents [9] . Medina and colleagues [7] have employed a genetically engineered mouse model to demonstrate that tumors can similarly become addicted to the expression of a miRNA -in this case, miR-21. This miRNA has previously been implicated in a variety of human cancers, by virtue of its frequent overexpression, and may also be associated with poor prognosis in some settings [10] [11] [12] .
Several previous reports have demonstrated that particular miRNAs, including miR-21, may also be required to maintain tumor cell survival, as revealed in cell culture and xenograft models [10, 13] . Medina et al. [7] have taken this a step further by demonstrating an apparent dependency on sustained miR-21 expression in a genetically engineered mouse model. MiR-155 is the only other miRNA that has been shown thus far to promote tumorigenesis when overexpressed in mice. Those animals developed acute lymphoblastic leukemia and high-grade lymphomas; however, it was not determined whether the resulting tumors remain dependent on sustained miR-155 expression [14] .
In the study by Medina et al. [7] the investigators established a mouse model in which miR-21 expression could be inducibly switched on or off. Transgenic animals demonstrated miR-21 overexpression in the brain, thymus, spleen, and the hematopoietic cell compartment. Following two months of induced miR-21 overexpression, the mice developed clinical signs of haematological malignancies, including enlarged lymph nodes and spleen. The specific pathology associated with miR-21 overexpression was pre-B-cell lymphoma, indicating that enforced miR-21 expression is sufficient to promote tumor initiation. Then, to determine whether sustained miR-21 expression was required to maintain malignancy, miR-21 expression was switched off. In a strikingly short period of time -less than a week -all of the tumor-bearing mice recovered from the observed clinical signs of haematological malignancies. More importantly, these animals all displayed rapid tumor regression upon miR-21 suppression, and a survival rate of 100% was observed when animals were examined after more than 3 months from the time that miR-21 expression had been switched off.
The observed rapid kinetics of tumor regression prompted the authors to establish whether miR-21 suppression promoted apoptosis. Notably, miR-21 has been previously shown to play an anti-apoptotic role by modulating the expression of genes such as BCL2 [10] , PTEN [15] , and PDCD4 [16] . Indeed, suppression of miR-21 resulted in a pronounced upregulation of early and late apoptotic markers. Moreover, co-administration of a general caspase inhibitor (Z-VAD-FMK) dampened this response and partially 'rescued' tumor regression, thereby directly implicating apoptotic tumor cell death in the response to miR-21 suppression. The investigators ruled out the formal possibility that de-differentiation of tumor cells could be a mechanism for the observed regression.
The oncogene addiction model is probably most significant in the context of oncoprotein-targeted cancer therapy. Among the most compelling examples to support the clinical significance of this model are BCR-ABL addiction in chronic myelogenous leukemia, EGFR addiction in non-small cell lung cancer, and ERBB2/HER2 addiction in breast cancer -settings in which inhibition of these oncogenic kinases is tightly associated with clinical benefit [17, 18] . With the more recent discovery of a plethora of non-coding RNAs within the human genome, including miRNAs, there has been considerable interest in determining whether these regulatory RNAs could similarly serve as therapeutic targets. Previous work has also reported examples of pre-clinical models in which inhibition of particular oncomiRs resulted in robust cell killing in vitro as well as inhibition of tumor growth in xenograft models [10, 13] . Such findings similarly support the concept of oncomiR addiction and, in fact, it was in one of those reports that the term oncomiR addiction was first proposed [13] .
The findings from Medina et al. [7] suggest that certain miRNAs, such as miR-21, may constitute important targets for therapeutic intervention in human cancer. However, a variety of technical and logistical challenges must first be overcome to enable the effective delivery of a miRNA-targeted agent to tumor cells in vivo. Moreover, it would most likely be necessary to identify, prior to treatment with such an agent, those tumors demonstrating a strict dependency on miR-21. Despite the relatively broad overexpression of miR-21 in various cancers [11] , it seems unlikely that all, or even most, tumors that overexpress miR-21 would demonstrate significant regression following miR-21 inactivation. Therefore, a more extensive analysis of miR-21 addiction in a large panel of cancer cell lines and mouse tumor models would be of considerable value in initially assessing the scope of miR-21 dependency across the cancer landscape. Such an analysis should also provide some perspective on the therapeutic index one would anticipate in the context of therapeutic targeting of miR-21. In this regard, it will also be of interest to determine the potential consequences of miR-21 disruption in normal tissues, which has not been reported thus far.
In light of the technical challenges associated with the direct targeting of miR-21, it may also be useful to identify the critical gene target(s) of miR-21 that mediate its oncogenic function, as one or more of these may constitute more pharmacologically tractable targets. Given that miR-21 has been shown to have multiple putative gene targets [10, 15, 16] , functional validation studies will be required to address this potentially complex issue. However, since miRNAs generally promote the repression of gene expression, and it is therefore not surprising to find that many of the established targets of oncomiRs are in fact tumor suppressor genes [15, 19, 20] , it may prove difficult to identify 'druggable' oncomiRregulated targets.
In sum, these new findings by Medina et al. [7] add yet another dimension to the oncogene addiction phenomenon. The possibility of targeting specific miRNAs required to maintain tumor cell survival as a therapeutic strategy is provocative, but is certainly a challenging prospect from a drug development and delivery standpoint. Future efforts will undoubtedly be required to establish the broader significance of oncomiR addiction, to identify the most relevant miRNAs in specific tumor indications, to establish the mechanisms by which miRNA overepression contributes to the maintenance of tumor cell viability, and to develop therapeutic strategies to inactivate specific miRNAs. And these are just the little things.
